allo-APZ2-CVU
|
30
|
NCT03257098
|
Chronic venous ulcer
|
topical
|
1 × 106 cells/cm2 wound surface
|
1 × 107 ABCB5+ MSCs in 1 ml HRG
|
dependent on wound size (max. 100 × 106)
|
1-ml syringe
|
1–10 syringes (dependent on wound size)
|
allo-APZ2-DFU
|
26
|
NCT03267784
|
Diabetic foot ulcer
|
topical
|
2 × 106 cells/cm2 wound surface
|
1 × 107 ABCB5+ MSCs in 1 ml HRG
|
1-ml syringe
|
1–10 syringes (dependent on wound size)
|
allo-APZ2-EB
|
23
|
NCT03529877
|
Epidermolysis bullosa (recessive dystrophic)
|
intravenous
|
2 × 106 cells/kg body weight
|
1 × 107 ABCB5+ MSCs in 1 ml HRG
|
dependent on body weight
|
10-ml syringe
|
1–2 syringes (dependent on body weight)
|
allo-APZ2-ACLF
|
3
|
NCT03860155
|
Acute-on-chronic liver failure
|
intravenous
|
1 × 107 ABCB5+ MSCs in 1 ml HRG
|
dependent on body weight
|
10-ml syringe
|
1–2 syringes (dependent on body weight)
|
allo-APZ2-PAOD
|
3
|
NCT03339973
|
Peripheral artery disease
|
intramuscular
|
7.5 × 106 cells per injection site (20–30 injection sites, depending on leg length)a
|
1 × 107 ABCB5+ MSCs in 1 ml HRG
|
150 × 106–225 × 106, dependent on leg length
|
1-ml syringe
|
20–30 syringes (number equal to the number of injection sites)
|